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Acute low-tone sensorineural hearing loss (ALHL) is a type of idiopathic sudden
sensorineural hearing loss. ALHL is rarely a solitary condition but rather co-occurs with
vertigo and tinnitus, being an element of contemporary diagnostic criteria for Menière’s
disease (MD). The goal of our present study was to determine the value of ALHL for the
early diagnosis of MD in patients presenting in the emergency room with ALHL as a main
complaint. The files of 106 patients with ALHL who were admitted to the emergency
room over the period of 7 years and 104 patients with acute high- tone sensorineural
hearing loss (AHHL) from the same period were included in this retrospective study.
Forty ALHL patients presented with recurrent episode of hearing loss and 66 remaining
patients presented with ALHL for the first time. Of the latter group, 25 patients gave
consent for the follow-up. First, we analyzed the difference in the occurrence of tinnitus
and vertigo between the ALHL and AHHL groups. In patients with ALHL, the incidence of
vertigo with tinnitus and the number of recurrent episodes were statistically higher than
in patients with AHHL. Next, we focused on the ALHL follow-up group (25 patients).
In that group, two patients had all MD symptoms at presentation, 18 had ALHL and
tinnitus and five ALHL only. Of 18 patients with ALHL and tinnitus at admission, five
developed vertigo and thus the triad of Menière’s disease. None of the five patients with
AHLH as a sole symptom developed MD during the follow-up time but four of them
have developed tinnitus. Patients with recurrent ALHL had significantly higher incidence
of MD than the patients with first episode. We conclude that some patients who present
with ALHL and concomitant tinnitus or have recurrent episodes of ALHL are more likely
to develop Menière’s disease than these patients, who present with ALHL as a sole
symptom. Nonetheless, we recommend otological follow-up for all patients presenting
with ALHL.
Keywords: acute low-frequency hearing loss, early diagnosis of Menière’s disease, sole symptom, comorbid
tinnitus, pure tone audiometry
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INTRODUCTION
Reported incidence of sudden idiopathic sensorineural hearing
loss (SSNHL) varies between the countries and ranges between
27/100,000 in the United States (1) and 168/100,000 in Germany
(2). Based on the frequencies affected by the hearing loss,
SSNHL can be divided into two subgroups: the acute high-
frequency hearing loss (AHHL), consisting of roughly 80% of
SSNHL cases and an acute low-frequency sensorineural hearing
loss traditionally called acute low-tone hearing loss (ALHL),
consisting of 17 to 23% of all SSHL cases (3). The low incidence
of ALHL is the reason behind infrequent studies and rather small
number of cases included in most of the ALHL reports (4–7).
In one large Japanese study, 642 patients diagnosed with ALHL
were evaluated over a period of 24 years in a national study
involving 23 hospitals (8). Another multi-center study conducted
at 30 hospitals from April 2014 to March 2016 reported 931
cases of ALHL (9). However, the diagnostic significance of ALHL
as a main complaint for the Meniere’s disease (MD) reminds
open.
Diagnostic criteria for MD include attacks of vertigo,
fluctuating ALHL, tinnitus and fullness in ear. Despite intensive
research, the etiology of MD is still under debate. In addition,
the diagnosis of MD remains challenging and subject of clinical
and scientific discussions in contemporary literature. In the
year 2015, Barany Society came up with new diagnostic criteria
for MD that differentiate between definite MD and a probable
MD. In addition to two or more episodes of vertigo and
fluctuating aural symptoms such as tinnitus or ear fullness, the
diagnostic criteria of definite MD include low- up to middle-
tone unilateral hearing loss during or after the vertigo attack
documented by pure tone audiometry. Hearing loss in the
affected ear should be not less than 30 dB in at least two
frequencies below 2,000Hz, as compared to the contralateral
ear. If both ears are affected, then the hearing loss should
be at least 35 dB, affecting at least two frequencies below
2,000Hz (10).
Hearing loss can occasionally precede the vertigo attacks
by months or even years, consistent with so called delayed
Menière’s Disease, therefore hindering the definite diagnosis
(11). Because the onset of MD typically coincides with hearing
loss, the interpretation of pure tone audiogram is a subject of
intense research. Morita et al. suggested that ALHL is defined
by the sum of hearing thresholds ≥ 70 dB in the frequencies
0.125, 0.250, and 0.5 kHz and the sum of the hearing thresholds
≤ 60 dB in the frequencies 2, 4 and 8 kHz (12). Further
studies have shown that MD patients with ALHL, frequently
had endolymphatic hydrops (13, 14). Junicho et al. found that
patients with recurrent ALHLs are more likely to be affected by
endolymphatic hydrops than patients with single ALHL episode.
In that particular study, 10% of patients developed definite
MD (15).
In our study, we wanted to assess the significance of
ALHL reported by the patients as a sole or main complaint,
for the prognosis of MD. Therefore, we characterized a
group of patients with ALHL using as a control a group
of patients with acute high-tone sensorineural hearing loss
(AHHL).
PATIENTS AND METHODS
Local Ethics Committee granted a permit for this retrospective
study (permit number EA1/116/14). First, we analyzed the data
of 1,136 patients who were admitted to the ER in our hospital
over the period of 7 years (2007–2013) with a sudden idiopathic
sensorineural hearing loss (SSNHL) that occurred no longer
than 3 weeks prior to admission. One hundred and six patients
with ALHL, who met the criteria of pure tone audiometry
characteristic for MD, were included in the study. As a control
group, 104 patients with an acute high- tone hearing loss (AHHL)
were included. All of these patients (ALHL and AHHL) were
seeking medical help solely because of sudden hearing loss (see
Figure 1) and some of them had additional symptoms, such as
tinnitus or vertigo; which, however, were not the reason for their
hospital admission.
Exclusion criteria included deafness, bilateral hearing loss,
neurological diseases and immunological diseases (Figure 1).
The presence of additional symptoms such as tinnitus and vertigo
was recorded as an answer to closed question “do you have
tinnitus?” or “do you have vertigo?.” Tinnitus-oriented diagnosis
was not performed, as ER in our hospital is not equipped for this
type of medical investigations. In addition, number of episodes
prior to admission (no episodes vs. recurrent episodes) was
recorded and analyzed.
In the ALHL group of patients, the first episode of hearing loss
was determined for 66 patients, 24 patients had the ALHL for the
FIGURE 1 | Flow chart of the study.
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second time, 5 patients had the third episode and 11 patients had
more than three episodes of ALHL. Of 40 patients withmore than
one episode of ALHL, 16 reported having vertigo.
Statistical Analyses
The statistical description and evaluation were performed using
the IBM SPSS Statistics software version 23. For the analyses
of frequency differences between the variables, we used the
chi-squared test with the alpha value <0.05. Additionally, we
used sensitivity/ specificity/ positive predictive value/ negative
predictive value of ALHL to diagnose Meniere’s disease in
comparison to the control group. The predictive value was
computed using Screening Validity feature of SPSS. Positive
predictive value for the presence of individual symptoms is
the probability that subjects who have given symptom will
develop MD. Negative predictive value is the probability that




Of 106 patients with ALHL, 63 (59.4%) were men and 43 (40.6%)
women, whereas in the control group of 104 patients with
AHHL, 71 (68.3%) were men and 33 (31.7%) were women. The
analysis indicated no statistically significant differences in gender
representation between the groups.
The average age of the ALHL patients was 45.01 ± 13.86
within a range 18–75 years whereas the age of control group
(AHHL) was on average 48.49 ± 14.35 years (range 20–
80). There were no significant differences in age between the
groups. However, there was a significant difference when the
age of patients at the occurrence of first episode was compared,
suggesting that ALHL patients were significantly older at first
presentation (mean age 47.92) than the AHHL patients age
at first presentation (mean age 44.55; p = 0.0001). Despite
its statistical significance, this finding is of minute clinical
relevance.
Comparison Between ALHL and AHHL
Groups Regarding Comorbid Symptoms
1. Tinnitus as comorbid symptom
There were no significant differences in the numbers of
comorbid tinnitus cases between the two sudden hearing loss
groups (Table 1, chi-squared test, p= 0.145).
2. Vertigo as comorbid symptom
The number of comorbid vertigo cases was significantly higher
in ALHL group (Table 2, chi-squared test, p = 0.0001). In the
ALHL group, 31 patients reported having vertigo.
3. Tinnitus and vertigo as comorbid symptoms (Triad of MD)
The number of comorbid vertigo and tinnitus cases was
significantly higher in ALHL group (Table 3, chi-squared test,
p = 0.002). The triad of MD occurred in 24.5 % of ALHL
group.
4. Frequency of repeated episode as comorbid symptom
The incidence of repeated hearing loss episodes was
significantly higher in ALHL group (Table 4, chi-squared test,
p= 0.002).
TABLE 1 | Tinnitus as comorbid symptom of ALHL.
Tinnitus Sum
positive negative
Type of SSNHL ALHL 80 26 106
AHHL 69 35 104
Sum 149 61 210
Sensitivity: 54.0 %, Positive predictive value: 75.5 %.
Specificity: 57.4 %, Negative predictive value: 33.7 %.
TABLE 2 | Vertigo as comorbid symptom of ALHL.
Vertigo Sum
positive negative
Type of SSNHL ALHL 31 75 106
AHHL 9 95 104
Sum 40 170 210
Sensitivity: 77.5 %, Positive predictive value: 29.2 %.
Specificity: 55.8 %, Negative predictive value: 91.3 %.
TABLE 3 | Tinnitus and vertigo as comorbid symptoms of ALHL.
Tinnitus and vertigo Sum
positive negative
Type of SSNHL ALHL 26 80 106
AHHL 8 96 104
Sum 34 176 210
Sensitivity: 76.5 %, Positive predictive value: 24.5 %.
Specificity: 54.5 %, Negative predictive value: 92.3 %.
TABLE 4 | Frequency of recurrent SSNHL as comorbid symptom.
Repeated episode Sum
positive negative
Type of SSNHL ALHL 40 66 106
AHHL 19 85 104
Sum 59 151 210
Sensitivity: 67.8 %, Positive predictive value: 37.7 %.
Specificity: 56.3 %, Negative predictive value: 81.7 %.
Differences Within the ALHL Group
In the group of patients with recurrent ALHL episodes, the
incidence of MD (Figure 2) was twice as high (37.1%) as in the
group with the first episode of hearing loss (16.7%).
Full diagnostic triad characteristic of MD was diagnosed at
admission in 9 patients with first ALHL episode, 9 patients with
the second ALHL episode, one patient with third ALHL episode
and in 5 patients with more than 3 ALHL episodes (total 24
patients).
Of 66 patients who had the ALHL for the first time, 25
patients were followed for 5 years upon signing a written consent:
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FIGURE 2 | Incidence of definite MD within the group presenting for the first
time with ALHL (65 patients) and the group presenting with recurrent ALHL (41
patients).
five presented with sole ALHL, 18 presented with ALHL and
tinnitus and two had full triad at presentation. Of five patients
who presented with sole ALHL, four had developed tinnitus but
reported no other symptoms during the follow up time. Of 18
patients who at presentation reported tinnitus in addition to
ALHL, five developed vertigo during the follow up; thus, qualified
for the diagnosis of definite MD (Figure 3).
The results of pure tone audiometry performed during the
admission were analyzed in subgroups of ALHL—“ALHL right
ear affected” and “ALHL-left ear affected”. The scores for each of
the frequencies tested (250, 500, 1,000, 1,500, 2,000, 3,000, 4,000,
6,000, and 8,000Hz) were compared individually between MD
and non-MD patients using one-way ANOVA and taking under
account the affected side. We found no statistical differences in
pure tone audiograms between the MD and non-MD groups.
There were more patients with greater hearing loss in the “full
MD symptoms” group than in the “incomplete symptoms” group.
In detail, of 24 patients who had full triad of MD symptoms, 10
patients (42% of that group) had hearing loss between 30 and 60
dB and 14 (58%) had a hearing loss of more than 60 dB. Of 82
ALHL patients without full triad of MD symptoms, 52 (63% of
that group) had a hearing loss between 30 and 60 dB and 30 (37%)
had a hearing loss more than 60dB.
Comorbid Conditions Within ALHL Group
In recent years, MD has been classified into five subtypes. Of
them, type 4 MD is characterized by comorbid migraine (16–
18) whereas type 5 by comorbid autoimmune disorders (19). To
determine the prevalence of this two types of comorbidities in
our cohort of subjects with ALHL, we searched for them in the
medical history which was available. We found no mention of
migraine headache. However, five of 106 patients with ALHL had
autoimmune diseases. In detail, three patients had Hashimoto
disease, one patient had Sjögren syndrome as well as lupus and
one patient had type 1 diabetes. Of the five autoimmune-positive
patients, two belonged to the group with definite MD at the
presentation with ALHL and three belonged to the group who
presented with ALHL for the first time but did not give their
consent for further follow-up.
DISCUSSION
Low-tone hearing loss is one of the diagnostic parameters used
to identify definite Menière’s disease (10). Although infrequent,
the sudden low-tone hearing loss ALHL occurs in some patients
who later develop MD. The open question in the field is how to
distinguish the ALHL without further health consequences from
ALHL, which will later transform into definite MD. Here, we
attempted to answer this question. We performed retrospective
study to identify clinical features associating with MD among the
patients diagnosed with ALHL.
The main finding of our study is that tinnitus reported
by patients during the first presentation with ALHL might be
indicative of developing or probable MD, even in the absence
of vertigo. However, the closed question used to determine
the presence of tinnitus was not followed by specialized
tinnitus diagnostic, such as tinnitus-oriented psychoacoustics
and psychometry, which was one of the limitations of this study.
Nevertheless, our results imply that ALHL as a sole symptom
does not predict MD, at least not within 5 years from the first
ALHL episode.
Using pure-tone audiometry, we were unable to identify
audiometric characteristics, which could be useful to discriminate
future MD patients. The audiograms of MD patients vary. At the
onset of MD, patients have typically upward sloping audiogram,
indicative of low-frequencies hearing loss. However, in the course
of disease, a downward sloping or a flat audiogram (pantonal
hearing loss) can develop (20–22). Friberg et al. have studied a
cohort of 161 MD patients and demonstrated that 21% of them
had pantonal hearing loss, 20% had upward sloping audiogram
and 28% had a notched audiogram. Fifteen years later, 74% of
patients in this cohort had pantonal hearing loss (23). Thomas
et al. studied audiograms of 610 MD patients and demonstrated
lack of MD-specific audiogram. The pantonal hearing loss
was most commonly represented whereas the upward sloping
audiogram was identified only in 12% of the cohort (24). In
our present study, we have observed the pantonal hearing loss
in 19% of the ALHL cases, whereas the remaining patients had
an upward sloping audiogram (data not shown). Hearing loss
occurring at theMD onset could still be fluctuating and therefore,
the audiometry may not be useful as a diagnostic criterion (25).
As the disease progresses, the hearing loss worsens, affecting
particularly the frequency of 500Hz (20), which stabilizes after
5–10 years from the disease onset at a hearing threshold ranging
between 50 and 60 dB and speech discrimination of 50–60% as
compared to healthy subjects.
A study, where the patients diagnosed with either ALHL,
AHHL or with MD were retrospectively analyzed, has
determined that 9% of 184 patients with ALHL have developed
MD over a course of time (15). Similar conclusions were drawn
in other work, where 45 patients with AHLH but without
vertigo were followed for 3 years and where 11% of these
patients have developed MD (26). In our present study, 24
patients (23%) with AHLH met the diagnostic criteria of MD
at presentation and further five patients (4.7%), who presented
with ALHL and tinnitus, developed MD over the follow-up time.
Interestingly, we observed increased incidence of MD in patients
who presented with recurrent ALHL (31.7%), as in the group
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FIGURE 3 | Flowchart visualizes changes in the MD-related health status of 25 patients with first episode of ALHL as a main complaint, who were followed up for 5
years.
presenting with ALHL for the first time (16.9%). In the control
AHHL group, one patient reported vertigo and was identified as
probable MD. Our results corroborate earlier finding of Junicho
et al. who demonstrated that 6% of AHHL patients may develop
Menière’s disease over a course of time (15).
Direct comparison of ALHL and AHHL groups suggested that
vertigo alone as well as vertigo with tinnitus–both were found
significantly more often in the ALHL group. Furthermore, the
recurrence of hearing loss episodes was seen more frequently in
ALHL than in AHHL group. Not much is known on this topic
in the literature because the ALHL is relatively rare. In addition,
diverse classification systems of ALHL used in various countries
complicate the matter (27, 28). In addition, the presence of
tinnitus in ALHL patients was rarely determined and taken
under account as a diagnostic factor. The four-panel charts
have demonstrated that tinnitus is not a suitable parameter
characterizing ALHL in patients with an acute hearing loss.
However, the sensitivity for the comorbid symptom vertigo
(alone and in combination with tinnitus) was quite high with 77.5
and 76.5 %. ALHL has therefore a high predictive value for the
recurrence of event.
Presence of comorbid conditions is an important parameter
in sub-classification of MD. We have screened the patients
medical files that were available to us for the presence of
such diseases, namely for comorbid migraine and autoimmune
diseases. Although no mention of migraine history was found
in the obtainable medical information, five ALHL patients had
autoimmune diseases (Hashimoto, Sjörgens and type 1 diabetes).
Two patients (one with Hashimoto diseases and one with type
1 diabetes) belonged to the group of 24 subjects diagnosed with
MD at the time of presentation, thus, confirming the findings of
others (19). Further three patients presented with ALHL for the
first time but have not given their consent for follow-up. Our
finding regarding this aspect of ALHL diagnosis suggest a need
for improvement of medical information collection. In fact, we
develop ALHL- and MD-specific extended questionnaire, which
upon approvement by our local ethics committee will be used in
our clinical routine. Some of the questions will specifically deal
with autoimmune diseases and migraine symptoms.
The main limitation of our study is its retrospective design
and—partly as a consequence of the design–a small number
of patients who gave their consent for follow-up. Future,
prospective studies should overcame this limitation. The second
limitation of our study is the small sample size and a very small
group of patients who were followed up after the first episode
of ALHL. The first one is a consequence of the ALHL incidence
whereas the second results from the fact that many patients came
to in our ER from out of town and after initial diagnosis, they
were taken over by a local specialist. Designing large multicenter
studies could overcome this obstacle. Third limitation of our
study is very restricted tinnitus-oriented diagnostics. Including
tinnitus-oriented psychoacoustics and psychometric instruments
in the future study would add valuable measurable information
on the topic.
In addition to vertigo and tinnitus, the ALHL remains an
important diagnostic criterion of MD. Other methods used to
diagnose MD, which include caloric test, electrocochleography
(ECochG), vestibular evoked myogenic potential (VEMP’s) and
the video Head Impulse Test (vHIT), often produce diagnostic
hints, but their sensitivity and specificity demonstrated so far in
clinical studies remains limited (29). The new diagnostic method
with a use of MRI and Gadolinium contrast media is useful for
the imaging of endolymphatic hydrops (30, 31), but the MD
symptoms not always correlate with the imaging results (29).
Our findings strongly imply the need for follow-up of
patients presenting with ALHL and tinnitus, because of
their increased risk to develop MD. To further study the
association between the ALHL, occurrence of comorbid
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symptoms and the positive development of MD, large
prospective multicenter and longitudinal studies are
essential.
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